Results 151 to 160 of about 5,099,009 (221)

Correction: Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]

Front Public Health
He J, Liu X, Yang Q.
europepmc   +1 more source

Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy. [PDF]

Kidney Med
Lv D, Sun P, Li Y, Liu T, Ye F, Yu Y, Li T, Liu A.   +7 more
europepmc   +1 more source

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +1 more source

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma. [PDF]

Curr Oncol
Puckrin R, Villa D, Fleury I, Larouche JF, Kuruvilla J.   +4 more
europepmc   +1 more source

Correction: Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies. [PDF]

Front Immunol
Li P, Xue X, Zhang Z.
europepmc   +1 more source

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]

Cancers (Basel)
Robak T, Wolska-Washer A, Robak P.
europepmc   +1 more source

Author response to Zhang and Chen. [PDF]

Br J Haematol
O'Reilly MA, Wilson W, Chaganti S.
europepmc   +1 more source

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'. [PDF]

J Cell Mol Med
europepmc   +1 more source

Vallecular Large B-Cell Lymphoma: An Uncommon Presentation of Follicular-Origin Disease. [PDF]

Cureus
Evans MJ, Sonnenburg AM, Elliott E, Otto AL, McIntire K.   +4 more
europepmc   +1 more source